2024
Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim results
2023
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
Alaiwi S, Roston T, Marstrand P, Claggett B, Parikh V, Helms A, Ingles J, Lampert R, Lakdawala N, Michels M, Owens A, Rossano J, Saberi S, Abrams D, Ashley E, Semsarian C, Stendahl J, Ware J, Miller E, Ryan T, Russell M, Day S, Olivotto I, Vissing C, Ho C. Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Circulation 2023, 148: 394-404. PMID: 37226762, PMCID: PMC10373850, DOI: 10.1161/circulationaha.122.062517.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic dysfunctionHypertrophic cardiomyopathyMedian ageHCM diagnosisVentricular assist device implantationCox proportional hazards modelComposite of deathVentricular systolic dysfunctionAssist device implantationVentricular ejection fractionProportional hazards modelCardiac transplantationSystolic dysfunctionEjection fractionHCM cohortPediatric cohortDevice implantationPoor outcomeSubsequent prognosisEchocardiographic reportsHazards modelPatientsAdult cohortPrognosisCohort
2020
Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced Cardiotoxicity
Feher A, Boutagy NE, Stendahl JC, Hawley C, Guerrera N, Booth CJ, Romito E, Wilson S, Liu C, Sinusas AJ. Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced Cardiotoxicity. JACC CardioOncology 2020, 2: 207-219. PMID: 34396230, PMCID: PMC8352292, DOI: 10.1016/j.jaccao.2020.05.007.Peer-Reviewed Original ResearchComputed tomography angiographyEpicardial coronary diameterGlobal longitudinal strainCoronary diameterCoronary vasoreactivityLeft ventricular ejection fraction reductionVentricular ejection fraction reductionLongitudinal strainCoronary Computed Tomography AngiographyEjection fraction reductionEpicardial coronary arteriesVentricular ejection fractionDoxorubicin-Induced CardiotoxicityChronic canine modelPrevention of doxorubicinEpicardial vasodilationVasodilator responseAngiography assessmentEjection fractionCumulative dosesCoronary arteryTomography angiographyPharmacological stressorVascular toxicityVascular endothelium